Spots Global Cancer Trial Database for acute lymphoblastic leukemia, in relapse
Every month we try and update this database with for acute lymphoblastic leukemia, in relapse cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse | NCT04475731 | Philadelphia-Po... Acute Lymphobla... | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | NCT04881240 | Acute Lymphobla... Acute Lymphobla... Pediatric ALL | CD19-CAR(Mem) T... Cyclophosphamid... Fludarabine Mesna CliniMACS Leukapheresis | - 21 Years | St. Jude Children's Research Hospital | |
| Study of Sequential CAR-T Cell Treating Leukemia Children | NCT04340154 | Acute Lymphobla... Acute Lymphobla... Refractory Acut... | chimeric antige... | 0 Years - 18 Years | Beijing Boren Hospital | |
| Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) | NCT03751072 | Acute Lymphobla... Acute Lymphobla... | 18 Years - | Group for Research in Adult Acute Lymphoblastic Leukemia | ||
| Venetoclax Basket Trial for High Risk Hematologic Malignancies | NCT05292664 | Myelodysplastic... Myelodysplastic... Myelodysplastic... Treatment-Relat... Therapy-Related... Acute Lymphobla... Acute Lymphobla... Lymphoblastic L... Lymphoblastic L... Acute Leukemia ... Acute Leukemia ... | Venetoclax Azacitidine Cytarabine Methotrexate Hydrocortisone Leucovorin Dexamethasone Vincristine Doxorubicin Dexrazoxane Calaspargase Pe... Erwinia asparag... | 1 Year - 40 Years | Dana-Farber Cancer Institute | |
| CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children | NCT04224571 | Acute Lymphobla... | Bortezomib Inje... rituximab injec... | 3 Months - 21 Years | Chinese University of Hong Kong | |
| CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction | NCT06389305 | B-cell Acute Ly... Acute Lymphobla... Refractory Acut... | peripheral bloo... CIK cell | 1 Year - 39 Years | Beijing GoBroad Hospital | |
| A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies | NCT05705570 | Acute Lymphobla... Acute Lymphobla... B-cell Lymphoma... B-cell Lymphoma... Chronic Lymphoc... Chronic Lymphoc... | Cyclophosphamid... Fludarabine Chimeric antige... | 2 Years - 70 Years | Hospital Israelita Albert Einstein | |
| Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD | NCT05137860 | Acute Lymphobla... Chemotherapeuti... Minimal Residua... | Bortezomib | 18 Years - 50 Years | Hospital General de Mexico | |
| A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies | NCT05705570 | Acute Lymphobla... Acute Lymphobla... B-cell Lymphoma... B-cell Lymphoma... Chronic Lymphoc... Chronic Lymphoc... | Cyclophosphamid... Fludarabine Chimeric antige... | 2 Years - 70 Years | Hospital Israelita Albert Einstein | |
| Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | NCT05779930 | Acute Lymphobla... Non-Hodgkin's L... Non-Hodgkin's L... Acute Lymphobla... B-cell Non Hodg... B Cell Leukemia | CD19 specific C... | - 30 Years | Nationwide Children's Hospital | |
| Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | NCT03573700 | Acute Lymphobla... Acute Lymphobla... | Cyclophosphamid... Fludarabine Mesna CliniMACS CD19- specific ... | - 21 Years | St. Jude Children's Research Hospital | |
| Study of Anti-CD22 CAR-T Cells Treating Leukemia Children | NCT04340167 | Acute Lymphobla... Acute Lymphobla... Refractory Acut... | Autologous huma... | 0 Years - 18 Years | Beijing Boren Hospital | |
| Study of Sequential CAR-T Cell Treating Leukemia Children | NCT04340154 | Acute Lymphobla... Acute Lymphobla... Refractory Acut... | chimeric antige... | 0 Years - 18 Years | Beijing Boren Hospital | |
| CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia | NCT04605666 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | CD19-CAR-T2 Cel... | 18 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | NCT05779930 | Acute Lymphobla... Non-Hodgkin's L... Non-Hodgkin's L... Acute Lymphobla... B-cell Non Hodg... B Cell Leukemia | CD19 specific C... | - 30 Years | Nationwide Children's Hospital | |
| Determining the Mechanisms of Loss of CAR T Cell Persistence | NCT05809284 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | - 25 Years | University College, London | ||
| Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | NCT04888442 | Acute Lymphobla... Refractory Acut... | pCAR-19B cells | 22 Years - 70 Years | Chongqing Precision Biotech Co., Ltd | |
| Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) | NCT03751072 | Acute Lymphobla... Acute Lymphobla... | 18 Years - | Group for Research in Adult Acute Lymphoblastic Leukemia | ||
| Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia | NCT06034561 | Acute Lymphobla... Acute Lymphobla... | Bortezomib | 16 Years - 60 Years | Instituto do Cancer do Estado de São Paulo | |
| CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia | NCT06316856 | T-Cell Acute Ly... Acute Lymphobla... Refractory Acut... | Autologous CD5 ... Previous stem-c... Newly matched d... | 1 Year - 70 Years | Beijing GoBroad Hospital | |
| Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | NCT04881240 | Acute Lymphobla... Acute Lymphobla... Pediatric ALL | CD19-CAR(Mem) T... Cyclophosphamid... Fludarabine Mesna CliniMACS Leukapheresis | - 21 Years | St. Jude Children's Research Hospital | |
| Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | NCT04888442 | Acute Lymphobla... Refractory Acut... | pCAR-19B cells | 22 Years - 70 Years | Chongqing Precision Biotech Co., Ltd | |
| Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) | NCT03751072 | Acute Lymphobla... Acute Lymphobla... | 18 Years - | Group for Research in Adult Acute Lymphoblastic Leukemia | ||
| Determining the Mechanisms of Loss of CAR T Cell Persistence | NCT05809284 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | - 25 Years | University College, London | ||
| Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO | NCT06025682 | Acute Lymphobla... Infections Bacterial Infec... Viral Infection Fungal Infectio... Acute Lymphobla... Acute Lymphobla... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
| Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia | NCT03957915 | Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Mixed Phenotype... | INA03 administr... | 18 Years - | Institut Paoli-Calmettes | |
| Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | NCT05779930 | Acute Lymphobla... Non-Hodgkin's L... Non-Hodgkin's L... Acute Lymphobla... B-cell Non Hodg... B Cell Leukemia | CD19 specific C... | - 30 Years | Nationwide Children's Hospital | |
| Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children | NCT04325841 | Acute Lymphobla... Acute Lymphobla... Refractory Acut... | Murine autologo... | 0 Years - 18 Years | Beijing Boren Hospital | |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies | NCT05292664 | Myelodysplastic... Myelodysplastic... Myelodysplastic... Treatment-Relat... Therapy-Related... Acute Lymphobla... Acute Lymphobla... Lymphoblastic L... Lymphoblastic L... Acute Leukemia ... Acute Leukemia ... | Venetoclax Azacitidine Cytarabine Methotrexate Hydrocortisone Leucovorin Dexamethasone Vincristine Doxorubicin Dexrazoxane Calaspargase Pe... Erwinia asparag... | 1 Year - 40 Years | Dana-Farber Cancer Institute | |
| Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT03515200 | Acute Lymphobla... Acute Lymphobla... | Palbociclib Ora... Intrathecal Tri... Dexamethasone Bortezomib Dasatinib Doxorubicin Ruxolitinib | - 21 Years | St. Jude Children's Research Hospital | |
| International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia | NCT03705507 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | Selumetinib Dexamethasone | - | University of Birmingham | |
| Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma | NCT06316427 | T-cell Acute Ly... Acute Lymphobla... Refractory Acut... | Autologous CD7 ... Prior-HSCT dono... New donor-deriv... | 1 Year - 70 Years | Beijing GoBroad Hospital | |
| Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT | NCT03389035 | Acute Lymphobla... | CARCIK-CD19 | 1 Year - 75 Years | Fondazione Matilde Tettamanti Menotti De Marchi Onlus |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
